| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2009 | US20090022803 Oral Formulations For Delivery of Catecholic Butanes Including Ndga Compounds |
| 01/22/2009 | US20090022801 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms |
| 01/22/2009 | US20090022799 Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use |
| 01/22/2009 | US20090022798 Formulations of nonopioid and confined opioid analgesics |
| 01/22/2009 | US20090022797 Stabilized tolterodine tartrate formulations |
| 01/22/2009 | US20090022796 Novel Substituted Benzimidazole Dosage Forms and Method of Using Same |
| 01/22/2009 | US20090022794 Topiramate Tablet Formulation |
| 01/22/2009 | US20090022793 Mesalamine suppository |
| 01/22/2009 | US20090022792 Vitamin D content uniformity in pharmaceutical dosage forms |
| 01/22/2009 | US20090022790 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 01/22/2009 | US20090022789 Enhanced formulations of lamotrigine |
| 01/22/2009 | US20090022788 Dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers |
| 01/22/2009 | US20090022787 Pharmaceutical composition comprising 11-deoxy- prostaglandin compound and method for stabilizing the compound |
| 01/22/2009 | US20090022786 Oral pharmaceutical dosage form and manufacturing method thereof |
| 01/22/2009 | US20090022783 siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES |
| 01/22/2009 | US20090022782 Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue |
| 01/22/2009 | US20090022780 Hydrogel |
| 01/22/2009 | US20090022778 External plaster containing flurbiprofen |
| 01/22/2009 | US20090022774 Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder |
| 01/22/2009 | US20090022771 Biomaterial |
| 01/22/2009 | US20090022770 Chitosan Compositions |
| 01/22/2009 | US20090022769 Medical Devices Comprising Polymeric Drug Delivery Systems With Drug Solubility Gradients |
| 01/22/2009 | US20090022758 Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia |
| 01/22/2009 | US20090022753 Surface proteins of streptococcus pyogenes |
| 01/22/2009 | US20090022746 Complexes for transferring nucleic acids into cells |
| 01/22/2009 | US20090022741 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging |
| 01/22/2009 | US20090022740 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging |
| 01/22/2009 | US20090022738 Multispecific deimmunized CD3-binders |
| 01/22/2009 | US20090022737 Aldos as modifiers of the igf pathway and methods of use |
| 01/22/2009 | US20090022732 Crystal of a cytochrome-ligand complex and methods of use |
| 01/22/2009 | US20090022729 Methods and compositions for treating cardiac dysfunctions |
| 01/22/2009 | US20090022726 Method of using il6 antagonists with proteasome inhibitors |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022712 Compositions and Methods for Inhibiting Leukocyte Function |
| 01/22/2009 | US20090022711 Methods of modulating cell death based on the bit-1/aes regulatory pathway |
| 01/22/2009 | US20090022709 Control of sorbose utilization genes and uses thereof |
| 01/22/2009 | US20090022708 Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| 01/22/2009 | US20090022707 contacting target cells with a therapeutic quantity of a soluble antibody that specifically binds tumor necrosis factor-related apoptosis inducing ligand receptor(TRAIL) DR5, and contacting target cells with a therapeutic agent |
| 01/22/2009 | US20090022706 Substituted cyclohexenes |
| 01/22/2009 | US20090022704 Method for the treatment of gout or pseudogout |
| 01/22/2009 | US20090022699 Method Of Genotypically Modifying Cells By Administration Of RNA |
| 01/22/2009 | US20090022689 C4-spiro-pyrrolidine antivirals |
| 01/22/2009 | US20090022688 Inhibitors of serine protease, particularly hcv ns3-ns4a protease |
| 01/22/2009 | US20090022686 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome |
| 01/22/2009 | US20090022685 Orthotopic, controllable, and genetically tractable non-human animal model for cancer |
| 01/22/2009 | US20090022683 Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof |
| 01/22/2009 | US20090022675 Esters with warming properties |
| 01/22/2009 | US20090022673 Composition and packaging method for animal dental care |
| 01/22/2009 | US20090022671 Treatment methods |
| 01/22/2009 | US20090022670 Novel compounds |
| 01/22/2009 | US20090022667 METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 |
| 01/22/2009 | US20090022656 Lipidated glycoprotein particles and methods of use |
| 01/22/2009 | US20090022623 Peptides Capable of Functioning as Mimotopes for Hormonal Analytes |
| 01/22/2009 | DE102007032977A1 Neue Cyclische Amide, Verfahren zu deren Herstellung und ihre Verwendung Novel cyclic amides, process for their preparation and their use |
| 01/22/2009 | DE102007032799A1 New sugar-containing polypyridine metal complexes e.g. useful as fluorescence markers in biological systems or for treating abnormal cells |
| 01/22/2009 | DE102007032662A1 Formulation for protecting skin aging caused by intrinsic or extrinsic factors, and for treating itching skin and atopic eczema, has apiogalacturonan or apiogalacturonan containing extract of Zostera marina and one or multiple hydrocolloids |
| 01/22/2009 | DE102006014320B4 Inhibitoren der löslichen Adenylatzklase Inhibitors of soluble Adenylatzklase |
| 01/22/2009 | CA2700477A1 Method for reducing intracranial pressure |
| 01/22/2009 | CA2699971A1 Spiro condensed barbituric acid derivatives for use as antibacterial |
| 01/22/2009 | CA2699891A1 Macrocyclic compounds as antiviral agents |
| 01/22/2009 | CA2697130A1 Novel one step process for preparing cross-linked poly(allylamine) polymers |
| 01/22/2009 | CA2696016A1 Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| 01/22/2009 | CA2695998A1 Novel heterocyclyl compounds |
| 01/22/2009 | CA2694983A1 Treatments of b-cell proliferative disorders |
| 01/22/2009 | CA2694748A1 Sodium channel inhibitors |
| 01/22/2009 | CA2694744A1 Methods for repelling arthropods using isolongifolenone and/or isolongifolenone analogs |
| 01/22/2009 | CA2694620A1 Solid preparation comprising alogliptin and metformin hydrochloride |
| 01/22/2009 | CA2694475A1 Quinazolinamide derivatives |
| 01/22/2009 | CA2693982A1 Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation |
| 01/22/2009 | CA2693969A1 Bioabsorbable elastomeric arterial support device and methods of use |
| 01/22/2009 | CA2693959A1 Inhibitors of beta amyloid production |
| 01/22/2009 | CA2693926A1 Dna-pk inhibitors |
| 01/22/2009 | CA2693904A1 Heterocyclic compounds useful as mk2 inhibitors |
| 01/22/2009 | CA2693887A1 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin inhibitors |
| 01/22/2009 | CA2693880A1 Pyrimidine derivatives 934 |
| 01/22/2009 | CA2693793A1 Anti-viral compounds, compositions, and methods of use |
| 01/22/2009 | CA2693623A1 Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| 01/22/2009 | CA2693594A1 Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| 01/22/2009 | CA2693590A1 Compounds and methods for treatment of sickle cell disease or complications associated therewith |
| 01/22/2009 | CA2693588A1 Sodium channel inhibitors |
| 01/22/2009 | CA2693577A1 Dry-powder medicament |
| 01/22/2009 | CA2693553A1 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 01/22/2009 | CA2693537A1 Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| 01/22/2009 | CA2693533A1 Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| 01/22/2009 | CA2693473A1 Thiadiazole modulators of pkb |
| 01/22/2009 | CA2693444A1 Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| 01/22/2009 | CA2693439A1 Pyridone gpr119 g protein-coupled receptor agonists |
| 01/22/2009 | CA2693406A1 Compounds and methods for modulating fxr |
| 01/22/2009 | CA2693369A1 Methods for treating anxiety |
| 01/22/2009 | CA2693232A1 Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| 01/22/2009 | CA2693216A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| 01/22/2009 | CA2693214A1 Beta carboline derivatives as antidiabetic compounds |
| 01/22/2009 | CA2693159A1 Sulfonamides as trpm8 modulators |
| 01/22/2009 | CA2693153A1 Target enzyme in the treatment of acne |
| 01/22/2009 | CA2693144A1 Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| 01/22/2009 | CA2693138A1 Aminoalkylazole derivatives as histamine-3 antagonists |
| 01/22/2009 | CA2693110A1 Methods for promoting wakefulness |
| 01/22/2009 | CA2693088A1 New antimicrobial compounds, their synthesis and their use for treatment of mammalian infections |